



October 17, 2017

## **Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017**

### **Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation**

STAMFORD, Conn., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at ANESTHESIOLOGY® 2017, the American Society of Anesthesiologists' annual meeting, to be held October 21-25, 2017 in Boston.

Presentations will include clinical trial data for CR845, Cara's first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.

Details for the presentations are as follows:

#### **CR845 Oral Abstract Presentation:**

**Title:** "Respiratory Effects of I.V. CR845: A Peripherally Acting, Selective Kappa Opioid Receptor Agonist"  
**Abstract Number:** JS01  
**Date / Time:** Sunday, October 22, 2017; 9:00 a.m. - 12:00 p.m. ET  
**Presenter:** **Eugene Viscusi, M.D.**, Director, Acute Pain Management, Thomas Jefferson University

#### **Satellite Symposium:**

**Title:** "A Potential New Path to Pain Relief: Multimodal Analgesia for Enhanced Recovery with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)"  
**Date / Time:** Sunday, October 22, 2017; 7:00 - 8:00 a.m. ET  
**Presenters:** **Joseph Stauffer, D.O., M.B.A.**, Chief Medical Officer, Cara Therapeutics  
**Christopher L. Wu, M.D.**, Professor, Division of Obstetric Anesthesiology, Division of Regional Anesthesia and Acute Pain Medicine, Department of Anesthesiology, The Johns Hopkins Hospital

For information about ANESTHESIOLOGY® 2017, visit [www.asahq.org/annualmeeting](http://www.asahq.org/annualmeeting).

### **About Cara Therapeutics**

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.

#### **INVESTOR CONTACT:**

Michael Schaffzin  
Stern Investor Relations, Inc.  
212-362-1200  
[michael@sternir.com](mailto:michael@sternir.com)

#### **MEDIA CONTACT:**

Annie Starr  
6 Degrees  
973-415-8838

[astarr@6degreespr.com](mailto:astarr@6degreespr.com)

 Primary Logo

Source: Cara Therapeutics, Inc.

News Provided by Acquire Media